{"groups":[{"description":"CCI779 and Bortezomib, Phase I part of this Phase I/II study","id":"FG000","title":"CCI779 and Bortezomib Phase I"},{"description":"CCI779 and Bortezomib, Phase II part of this Phase I/II study","id":"FG001","title":"CCI779 and Bortezomib Phase II"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"43"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Between June, 2007, and December, 2009, we enrolled patients into our open-label, dose-escalation study at three centres in the USA (Dana-Farber Cancer Institute, Boston, MA; Washington University, St Louis, MO; and the University of Michigan, Ann Arbor, MI)."}